Category: Finance
Resources Top 4: A rare earths ‘gamechanger’, parabolic copper juniors, and the most dangerous gold target you’ve ever seen
Mako Gold maps targets for drill testing at ~870,000oz Napié flagship in Côte d’Ivoire Cobre dials in on giants along Kalahari Copper Belt Kairos says [more…]
ASX Small Caps Lunch Wrap: Who’s directing their misplaced rage at the Mona Lisa this time?
Local markets are doing something this morning. At 10.30am, it was a whole lotta nuthin, though – despite what some would call a “modest rise” when [more…]
Long Shortz with Belararox: Field work activities uncover exciting results in Argentina
Geochemical sampling work at the TMT project identifies 12 potential drill targets across the Toro-Malambo-Tambo project. Stockhead’s Ashtyn Hiron sits down with Belararox (ASX:BRX) exploration [more…]
Eagle Mountain’s move to start Oracle Ridge scoping study lifted by bullish copper
Eagle Mountain to start scoping study to define the production pathway for its Oracle Ridge copper project in Arizona Scoping study to include simplified flowsheet, [more…]
ASX Quarterly Wrap: Prospect reels in high-grade African lithium and the drill bit keeps spinning at Chariot’s Black Mountain project
It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with update lodgements. To save you the trouble of trudging through [more…]
Alma Metals hits copper and molybdenum at Briggs with resource drilling planned for Q2
Recently completed core drilling at the Briggs project has intersected a thick zone of copper-molybdenum mineralisation from surface Assays for the remaining holes are expected [more…]
ASX Health Stocks: Starpharma says Viraleze reduces viral load in nose, effective in Covid-19
Starpharma says Viraleze is effective in COVID-19 patients Neurotech to start Phase I/II clinical trial after Ethics approval FDA requests more information from PharmAust’s Orphan [more…]
Bioxyne’s Q2 FY24 revenue surpasses $2.5m on Aussie medicinal cannabis growth
Bioxyne attains annualised revenue run rate of $10 million, with Q2 reaching $2.56 million TGA GMP audit completed with issuance of GMP manufacturing license expected [more…]
FDA offers PharmAust clear guidance for orphan drug designation approval
FDA seeks clinical trial data from PharmAust to support its Orphan Drug Designation in the treatment of MND/ALS PharmAust to unveil Phase 1 MEND Study [more…]
Enivo pilot clinical study shows promise for reducing mastectomy complications
AROA’s Enivo system shows promise in management of dead space following mastectomy All enrolled patients so far have successfully undergone a unilateral mastectomy and follow-up, [more…]
